running early-stage programs, recognizing this decoupling early can sharpen dose optimization  and de-risk

✅ The sooner you understand what they’re optimizing for, the faster you can align your strategy to de-risk

Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation

GPCR drugmaker Septerna amasses $288M in IPO Surrounded by AI bio giants, tiny startup Nabla Bio makes de

Therefore, matching a ligand to an orphan GPCRs, the process of de-orphanizing, is of great importance

Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics

Learn how to transform your program from a series of disconnected efforts into a predictable, de-risked

Seven transmembrane receptors as nature's prototype allosteric protein: de-emphasizing the geography Manchanda Y, ElEid L, Oqua AI, Ramchunder Z, Choi J, Shchepinova MM, et al. Protein Eng Des Sel. 2016;29(12):583-594. 47.         Crilly SE, Ko W, Weinberg ZY,Puthenveedu MA.

This week's highlight includes congrats to: Tessa de Vries, Graham Ladds, Antoinette MaassenVanDenBrink

ended 31 December 2022 Addex Raises $5.0 Million in Equity Financing Testing the limits of SMILES-based de

Bénard, G., Ramos, A., Reguero, L., Arrabal, S., Elezgarai, I., Gerrikagoitia, I., Suarez, J., Rodríguez De

Cary, B.P., et al., New Insights into the Structure and Function of Class B1 GPCRs.  

G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D.

.; Van De Veen, W.; Akdis, M.; Ortega-Gutiérrez, S.; López-Rodríguez, M. L.; Akdis, C.